Ascentage Pharma Reports the US FDA’s Clearance to Commence the P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Leukemia
Shots:
- The US FDA has granted clearance to Ascentage Pharma for commencing a global registrational P-III study of olverembatinib (HQP1351) in H1’24
- The open-label, randomized, registrational P-III study aims to evaluate the safety and efficacy of olverembatinib for the treatment of patients with CML-CP with/without T315I mutation
- Olverembatinib (approved in the Chinese mainland) is a third-generation BCR-ABL inhibitor that targets BCR-ABL and a range of BCR-ABL mutants incl. the T315I mutation
Ref: Ascentage Pharma | Image: Ascentage Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
